Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
22.12
EV/EBITDA
2.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.5
Face value
--
Shares outstanding
41,879,000
CFO
$-11.99 Mln
EBITDA
$7.04 Mln
Net Profit
$28.31 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
| -56.7 | 13.7 | -42.5 | -93.5 | -64.8 | -25.8 | -5.1 |
|
BSE Sensex*
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
| -83.0 | -53.1 | 34.3 | -21.9 | 366.0 | -37.5 | 44.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ProPhase Labs Inc. (DE) (PRPH)
|
0.3 | 13.4 | 0.7 | -81.5 | -4,703.1 | -358.2 | -- | 2.2 |
| 170.5 | 5,525.0 | 964.5 | 136.5 | 19.9 | 11.4 | 40.6 | 4.5 | |
| 65.3 | 8,466.9 | 2,192.1 | 281.0 | 14.7 | -- | 31.2 | 0.0 | |
| 33.8 | 5,398.0 | 5,502.5 | 171.6 | 2.8 | 3.8 | 31.9 | 1.3 | |
| 89.6 | 4,269.0 | 1,014.6 | 15.6 | 2.1 | 1.5 | 291.7 | 4.1 | |
| 141.0 | 9,008.7 | 7,361.0 | 628.0 | 14.0 | 15.5 | 14.8 | 2.3 | |
| 167.5 | 4,672.7 | 1,886.5 | 169.7 | 9.3 | 17.5 | 27.6 | 4.6 | |
| 18.0 | 2,752.4 | 3,076.2 | 225.3 | 13.2 | 8.5 | 11.5 | 0.9 | |
| 51.2 | 11,559.8 | 17,979.4 | 1,208.1 | 9.7 | 32.9 | 9.6 | 3.7 | |
| 110.4 | 6,125.7 | 7,884.6 | 357.3 | 7.8 | 9 | 19.5 | 1.6 |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements... under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Address: 711 Stewart Avenue, Garden City, NY, United States, 11530 Read more
Chairman & CEO
Mr. Ted William Karkus
Chairman & CEO
Mr. Ted William Karkus
Headquarters
Garden City, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ProPhase Labs Inc (DE) (PRPH) stood at $ 94 Mln as on 31-Mar-25
The share price of ProPhase Labs Inc (DE) (PRPH) is $0.33 (NASDAQ) as of 20-May-2025 16:29 EDT. ProPhase Labs Inc (DE) (PRPH) has given a return of -64.82% in the last 3 years.
ProPhase Labs Inc (DE) (PRPH) has a market capitalisation of $ 13 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ProPhase Labs Inc (DE) (PRPH) is 2.20 times as on 20-May-2025, a 2% premium to its peers’ median range of 2.16 times.
Since, TTM earnings of ProPhase Labs Inc (DE) (PRPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ProPhase Labs Inc (DE) (PRPH) and enter the required number of quantities and click on buy to purchase the shares of ProPhase Labs Inc (DE) (PRPH).
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Address: 711 Stewart Avenue, Garden City, NY, United States, 11530
The CEO & director of Mr. Ted William Karkus. is ProPhase Labs Inc (DE) (PRPH), and CFO & Sr. VP is Mr. Ted William Karkus.
There is no promoter pledging in ProPhase Labs Inc (DE) (PRPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,083
|
|
|
870
|
|
|
806
|
|
|
603
|
|
|
583
|
|
|
533
|
|
|
456
|
|
|
377
|
|
|
274
|
| ProPhase Labs Inc. (DE) (PRPH) | Ratios |
|---|---|
|
Return on equity(%)
|
-358.22
|
|
Operating margin(%)
|
-4703.07
|
|
Net Margin(%)
|
-12493.56
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ProPhase Labs Inc (DE) (PRPH) was $0 Mln.
$0.01
(
